Stanley I. Gutiontov et al. revealed that CDKN2A negatively impacts clinical outcomes in advanced NSCLC treated with immune checkpoint blockade therapy and the survival analysis also suggested NSCLC patients carrying CDKN2A-mutation have a poor prognosis [18]. The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.